Smart ECM
Account
RESStudio E.R. Congressi S.R.L.Evento 476838 / Edizione 1

2Nd Bologna workshop on immunotherapy for acute myeloid leukemia

Workshop internazionale RES su immunoterapia per leucemia mieloide acuta (AML): microambiente immunologico, cellule NK, CAR-T, inibitori menin, biomarker immunologici, omics. 29-30/09/2026, Royal Hotel Carlton, Bologna. RS: Antonio Curti. 4,9 crediti ECM.

Provider
Studio E.R. Congressi S.R.L.Studio E.R. Congressi S.R.L. (828)
Crediti ECM
4,9
Costo
Gratuito
Durata
7 ore
Date
29 - 30 settembre 2026
Richiedi info iscrizione
Aggiungi al Piano

Razionale scientifico

Acute Myeloid Leukemia (AML) is a heterogeneous clonal disease deriving from a rare population of bone marrow leukemic stem cells. Although new and potent drugs have recently entered the clinical stage, the 5-year patient overall survival is largely unsatisfactory, reaching 30% and dropping to 5-10% in the elderly. Therefore, there is an urgent and unmet need for effective new treatment modalities for AML. In the last years, cancer immunotherapy is gaining much interest due to its unique characteristics, such as the absence of conventional drug resistance mechanisms and low grade of toxicity. In AML, the immunotherapy field is evolving and expanding. Immunological drugs, i.e. immune checkpoint inhibitors, have been tested in early clinical trials and monoclonal antibodies as well as adoptive immunotherapy strategies are under active investigation. Despite a strong rationale, the clinical results of these approaches have not been satisfactory, and several questions need to be answered for a full exploitation of immune interventions in AML. Among them, the immunological effects of current therapies, such as chemotherapy agents, IDH1 inhibitors, FLT3-inhibitors, hypomethylating agents, BCL2 inhibitors, the contribution of drivers gene mutations on the immune microenvironment and their relevance for immunotherapy are still poorly investigated. The aim of the workshop is to discuss recent biological findings which strongly indicate the specificity of bone marrow immune microenvironment as a critical issue for an effective biology-driven development of immunotherapies in AML, and to provide novel insights to move a step forward by designing a new generation of combination clinical trials.

Luogo

Royal Hotel Carlton
Via Montebello, 8, Bologna (BO)

Programma

Day 1 - Martedi 29 Settembre
  • 14:00WelcomeM. Seri, P.L. Zinzani
  • 14:10Rationale and goals of the workshopA. Curti
  • 14:20Lecture: Clonal evolution in myeloid neoplasms and inflammatory stromal remodeling: implications for immunotherapyM.H.G.P. Raaijmakers
  • 14:50Leukemia hematopoietic hierarchies and differentiation stateS.C. Renders
  • 15:10AML genomic landscape: focus on IDH1 and FLT3J. Nanni
  • 15:30Leukemia epigenetic remodelling: the lesson of allogeneic stem cell transplantationL.A.E. Vago
  • 15:50Epithelial-to-mesenchymal transitionS. Sangaletti
  • 16:10Leukemic cell metabolic profileG. Simonetti
  • 16:30Coffee break
  • 16:50Inflammation and T-cell dysfunctionalityS. Rutella
  • 17:10Reprogramming the cytotoxic architecture of NK cellsK.J. Malmberg
  • 17:30Bone marrow immune cells aggregationO. Heidenreich
  • 17:50Immune dysregulation dominance and poor outcome: when MDS looks like AMLS.Y. Kordasti
  • 18:10Aging and immune bone marrow microenvironmentC. Waskow
Day 2 - Mercoledi 30 Settembre
  • 08:45Introduction of the second dayA. Curti
  • 09:00Dendritic cell immunotherapy in myeloid leukemiaB.T. Gjertsen
  • 09:20AML-directed CAR T-cell therapies: where we standM. Subklewe
  • 09:40Combination backbone for immunotherapies: focus on Aza-VenA. Curti
  • 10:00Menin inhibition: NPM1 and immune microenvironment + menin inhibitorsM.P. Martelli, C. Papayannidis
  • 10:45Coffee break
  • 11:00Spatial omicsJ.C. Schröder
  • 11:20Amino acids and tryptophan metabolitesC.A. Opitz
  • 11:403D modelsU. Riekstina
  • 12:00Extracellular vesiclesD. Forte
  • 12:20Real-time immunometabolismR.J. Argüello
  • 12:40Final discussion and concluding remarksA. Curti

Responsabili del corso

STUDIO E.R. CONGRESSI S.R.L.

Provider

ID Provider: N° 828

Città: Bologna (BO)

Tipologia: Società, Agenzie Ed Enti Privati

Stato accreditamento: Standard - 1° Rinnovo

  • Antonio Curti

    Responsabile scientifico

    Specializzazione: Ematologia

    Struttura: Policlinico Sant'Orsola-Malpighi, Bologna

    Ruolo: Dirigente Medico I Livello, Istituto di Ematologia e Oncologia Medica

Relatori e docenti

  • Rafael José Argüello

    Relatore

  • Matteo della Porta

    Moderatore

  • Dorian Forte

    Relatore

    Specializzazione: Scienze Biomediche

    Struttura: Istituto di Ematologia Seragnoli, Bologna

    Ruolo: Ricercatore

  • Bjorn Tore Gjertsen

    Relatore

    Specializzazione: Ematologia

    Struttura: University of Bergen, Norway

    Ruolo: Professor

  • Olaf Heidenreich

    Relatore

    Specializzazione: Ematologia

    Struttura: Princess Maxima Center, Utrecht, NL

    Ruolo: Professore

Domande frequenti

L'evento è accreditato per: Medico Chirurgo (Oncologia, Ematologia).

Fonte dati per questo evento: Agenas. Evento organizzato da provider terzo. Smart ECM riporta dati pubblici dell'evento a scopo informativo e non è responsabile né del corso né dei contenuti, né ha accordi commerciali o di collaborazione con il provider.

Sei un provider ECM?

Contattaci per scoprire come possiamo collaborare.

Contattaci